Dr. Justin Mathew Rineer, MD

Dr. Rineer practices at Arnold Palmer Hospital for Children in Orlando, Florida.

Dr. Rineer's NPI, 1750588075, was assigned on June 29, 2007. Dr. Rineer graduated from SUNY Downstate Health Sciences University in 2004. Dr. Rineer holds Florida license ME107121.

Dr. Rineer's primary practice is Arnold Palmer Hospital for Children, at 92 W Miller St, Orlando, FL 32806 in Orange County. The practice phone is (407) 650-5028.

Dr. Rineer's primary practice is Arnold Palmer Hospital for Children in Orlando, Florida. Dr. Rineer is also affiliated with AdventHealth Orlando. The medical group on file is Orlando Health Medical Group. Dmand AI also links Dr. Rineer to 4 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rineer practices, 7 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Rineer's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Rineer is board certified in radiation oncology by the American Board of Radiology. Dr. Rineer is licensed in Florida.

Dmand AI lists bone cancer radiation, head & neck cancer radiation and lung cancer radiation among the conditions Dr. Rineer treats.

CMS data shows 1,598 Medicare services from Dr. Rineer across 16 procedure codes in 2024, for 269 Medicare patients. Medicare paid $107,803 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 269 Medicare patients who saw Dr. Rineer in 2024. The largest group is 65 to 74, with 129 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 1.94, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rineer's median patient age at 73, with 37% women.

In 2024, Dr. Rineer wrote 130 Medicare Part D claims for 61 patients. 90% of them were for generic drugs. CMS names the drug for 51 of them, across 4 drugs with 11 or more claims each, at $971 in total drug cost. In 2023, CMS named 18 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Dr. Rineer for performance year 2024, reported as part of a group. Dr. Rineer accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rineer as offering telehealth.

Dmand AI links 56 papers to Dr. Rineer, published from 2009 to 2025. 2014 was the busiest year, with 9. The most frequent topics are Lung Neoplasms, Prostatic Neoplasms and Radiotherapy, Adjuvant. Dr. Rineer has published most often in Int J Radiat Oncol Biol Phys. Dr. Rineer's most frequent co-authors are Andrew Thomas Wong, MD, Patrick Kelly, MD and Evangelia Katsoulakis, MD.

Dmand AI links Dr. Rineer to 4 clinical trials, 2 of them phase 3 studies. Conditions studied include Carcinoma, Non-Small-Cell Lung, Lung Neoplasms and Carcinoma, Bronchogenic. Alliance for Clinical Trials in Oncology sponsors the most, 2.

CMS Open Payments shows 29 general payments to Dr. Rineer from 6 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 72% of the total. Siemens Medical Solutions USA, Inc. paid the most, $9,044.

Dr. Rineer graduated from SUNY Downstate Health Sciences University in 2004.

Dr. Rineer is in network with 16 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.